Toronto Congress Centre

THE LIVING LUXE DESIGN SHOW PRESENTED BY JENNAIR BRINGS IN A NEW ERA OF CANADIAN LUXURY APRIL 19-21, 2024

Retrieved on: 
星期二, 十二月 12, 2023
Principal, Toronto Congress Centre, Official, KOHLER, Creativity, John Inglis and Company, Hospital, Experience, House, Marketing, JennAir, Creative, Exhibition, LMD, Architecture, Retail, Industrial design, Interior design, Tourism

TORONTO, Dec. 12, 2023 /CNW/ - The Living Luxe Design Show (LLDS) is set to enhance Toronto's cultural landscape with its return in 2024, taking center stage in an unparalleled, grand-scale exhibition.

Key Points: 
  • TORONTO, Dec. 12, 2023 /CNW/ - The Living Luxe Design Show (LLDS) is set to enhance Toronto's cultural landscape with its return in 2024, taking center stage in an unparalleled, grand-scale exhibition.
  • "As a brand that is committed to pushing boundaries and redefining luxury, JennAir is thrilled to partner with Living Luxe as the presenting sponsor of their 2024 Design Show.
  • Lori brings a tour-de-force of forward-thinking design inspiration that truly encapsulates the essence of luxury design.
  • Industry Expert Discussions on the JennAir Stage:
    Industry experts will grace the stage, including a fascinating discussion on Disrupting Design with JennAir.

Zip to Host Customer Session With ADT at SAP Spend Connect Live

Retrieved on: 
星期一, 十月 9, 2023
Software, Technology, Payments, Spend, Messe Wien, Cifuentes, Travel, Channel, ADT, Toronto Congress Centre, Music, Research

Zip , the world’s only intake-to-pay platform, is attending SAP Spend Connect Live and is leading a customer session onsite with ADT.

Key Points: 
  • Zip , the world’s only intake-to-pay platform, is attending SAP Spend Connect Live and is leading a customer session onsite with ADT.
  • Zip is the only approved intake partner at the event listed in the SAP App Store .
  • Commencing today and running through Wednesday, October 11, 2023, SAP Spend Connect Live is the premier spend management user conference and brings together procurement, finance, travel and expense, and business network experts.
  • In their session, Zip’s Hall and ADT’s Cifuentes will explore how ADT leverages intake through Zip to support digital transformation efforts.

ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress

Retrieved on: 
星期五, 九月 22, 2023
Abstract, ASLN, Atopic dermatitis, Publication, Journal of the European Academy of Dermatology and Venereology, Toronto Congress Centre, Patient, SAN, Messe, Pharmaceutical industry, Dermatology, Venereology

SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that four abstracts on eblasakimab and farudodstat have been accepted for e-poster and oral presentations at the 32nd European Academy of Dermatology and Venereology (EADV), taking place from October 11 to 14, 2023, in Berlin, Germany, at the Messe Congress Centre.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that four abstracts on eblasakimab and farudodstat have been accepted for e-poster and oral presentations at the 32nd European Academy of Dermatology and Venereology (EADV), taking place from October 11 to 14, 2023, in Berlin, Germany, at the Messe Congress Centre.
  • Abstract 1 (late-breaker) : Results from TREK-AD: a randomized, double-blind, placebo-controlled, Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (Abstract ID 6703)
    The posters will be available to view online in the Publications section of ASLAN’s website following presentation.

Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
星期三, 九月 6, 2023
Health, Surgery, General Health, Research, Science, Pharmaceutical, Optical, Cataract surgery, Surgeon, Very-small-aperture terminal, Refractive surgery, Aperture, Safety, Bausch, DRS, PRK, Bausch & Lomb, Toronto Congress Centre, Physician, CEST, Range, European Society for Primary Immunodeficiencies, Cataract, IOL, NYSE, Combination, MIMS, Telescope, Hospital, Dentistry, Silviculture, Medical device, Patient

Safety and performance results of the enVista® ENVY, an investigational premium IOL

Key Points: 
  • Safety and performance results of the enVista® ENVY, an investigational premium IOL
    Refractive outcomes of a low 0.90 diameter cylinder for the investigational enVista Toric IOL.
  • Bausch + Lomb will also host several educational and networking events during the meeting.
  • Other presentations featuring the company’s latest surgical technology will take place in the Bausch + Lomb booth, and Bausch + Lomb will host a Lift Off Celebration event to mark its 170th anniversary.
  • “Evaluation of Visual Outcomes in Patients with Complex Corneas Implanted with the IC-8 IOL.” J. Mehta et al.

Johnson & Johnson Vision announces launch of ELITA™ Platform to Correct Myopia with New SILK Procedure at the European Society of Cataract and Refractive Surgeons Congress

Retrieved on: 
星期三, 八月 30, 2023
Presbyopia, Johnson & Johnson Vision, Natural Resources, A4, Patient, Near-sightedness, Congress, Environment, Johnson, Element, EDOF, Small incision lenticule extraction, Ophthalmology, Cataract, Woman, Symposia, Abstract, The New Elite, Eye, Carbon, Lock (computer science), Intraocular lens, Cornea, Surgeon, SILK, Food, IIS, Recycling, Toronto Congress Centre, Astigmatism, European Society of Clinical Microbiology and Infectious Diseases, Health, Dentistry, Telescopic sight, Pharmaceutical industry, Software

LONDON, Aug. 30, 2023 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of Johnson & Johnson MedTechi, will announce the launch of a next-generation laser vision correction solution, the ELITATM Platform, at the 41st European Society of Cataract and Refractive Surgeons (ESCRS) congress, 8-12 September 2023. The congress will also showcase a range of breakthrough data, with over 30 abstracts supported by Johnson & Johnson Vision accepted for presentation.

Key Points: 
  • The congress will also showcase a range of breakthrough data, with over 30 abstracts supported by Johnson & Johnson Vision accepted for presentation.
  • The ELITATM Platform enables surgeons to perform refractive correction on patients with myopia, with or without astigmatism, using the new SILK (Smooth Incision Lenticule Keratomileusis) procedure.
  • The Johnson & Johnson Vision ESCRS Booth (#B202) will have live demonstration areas for surgeons to experience first-hand the ELITATM Femtosecond Laser as well as other leading Johnson & Johnson Vision products.
  • Additionally, attendees will be able to participate in the Toric VR Simulator experience alongside dry labs and meet the expert sessions at the booth and in the Johnson & Johnson Vision Lighthouse.

Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023

Retrieved on: 
星期三, 六月 7, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract, EASL, Autoimmune hepatitis, Medication, Toronto Congress Centre, Sphingolipid, Viral, Poster, European Association for the Study of the Liver, Pharmaceutical industry, Liver

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 being held June 21 – 24, 2023 in Vienna, Austria at the Messe Wien Exhibition Congress Centre.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 being held June 21 – 24, 2023 in Vienna, Austria at the Messe Wien Exhibition Congress Centre.
  • In the poster, Enanta’s HSD17B13 inhibitors, which have previously been shown to be anti-inflammatory in vivo with modulation of sphingolipids, were evaluated in a mouse model of autoimmune hepatitis for anti-inflammatory and hepatoprotective effects.
  • The full scientific program for The International Liver Congress 2022, as well as the abstracts, can be found at https://www.easlcongress.eu/ .

Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses

Retrieved on: 
星期五, 五月 19, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Volunteering, European Hematology Association, APS, Lupus, SLE, European Congress of Radiology, Festhalle, Autoimmunity, Toronto Congress Centre, ALPN, EHA, EULAR, Treatment, Inflammation, Pharmaceutical industry, Vaccine, Tolerability, Safety, Pharmacokinetics

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hematology Association (EHA).

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hematology Association (EHA).
  • Presentation Title: A Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus Erythematosus
    Session Name: Short Oral Presentation Session 16, SLE Treatment 2
    Poster Title: A Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus Erythematosus and Other B Cell-Related Disorders (RUBY-1)
    Session Name: A novel journey into SLE, Sjögren's and APS
    Poster Title: Povetacicept (ALPN-303), A Potent Dual BAFF/APRIL Antagonist, for the Treatment of Autoimmune Cytopenias and Other Antibody-Related Diseases
    Location: Panorama 2, Congress Centre, Forum, Festhalle and Halls 1 and 3 of Messe Frankfurt, Frankfurt, Germany
    Presentation Title: Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept for Autoimmune Glomerulonephritides

Media Invite: Sports Legend Billie Jean King To Deliver Keynote at TRREB REALTOR® QUEST

Retrieved on: 
星期三, 五月 10, 2023
Toronto Congress Centre, Women's Sports Foundation, Toronto, AND, Social justice, Map, Toronto Regional Real Estate Board, Sport, Women's Tennis Association, Billie Jean, Nightclub

TORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- Media are invited to attend a keynote address by sports icon and champion of equality and inclusion, Billie Jean King , at TRREB REALTOR® QUEST on May 17.

Key Points: 
  • TORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- Media are invited to attend a keynote address by sports icon and champion of equality and inclusion, Billie Jean King , at TRREB REALTOR® QUEST on May 17.
  • Billie Jean King is a former world number one professional tennis player, winner of 39 Grand Slam titles, an author, and a prominent social justice activist.
  • She founded the Women's Tennis Association, the Women's Sports Foundation, and the Billie Jean King Leadership Initiative.
  • The Toronto Regional Real Estate Board is Canada’s largest real estate board with almost 70,000 residential and commercial professionals connecting people, property and communities.

FRENCH TECH: A Promising Start for the New Line of Medication Safety Robots AIDE in France

Retrieved on: 
星期三, 五月 10, 2023
General Health, Health, Electronic Design Automation, Medical Devices, Robotics, Technology, Other Technology, Other Health, Strasbourg, AIDE, Hospital, Toronto Congress Centre, Patient, Patient safety, Nursing, Safety, Approximation error, Medical device

The first contract was signed with the Charles Perrens Hospital in Bordeaux to supply the AIDE-CUT , Deenova's drug safety automation system for tablet cutting and repackaging of all types of drugs.

Key Points: 
  • The first contract was signed with the Charles Perrens Hospital in Bordeaux to supply the AIDE-CUT , Deenova's drug safety automation system for tablet cutting and repackaging of all types of drugs.
  • When repackaging unit dose medications, the AIDE-CUT ensures maximum accuracy and safety.
  • The system is outfitted with high-tech sensors that detect and correct errors in real time, ensuring that the cutting and repackaging processes are optimized.
  • The AIDE-PICK improves patient safety, reduces medication errors, and maximizes operational efficiency by ensuring full medication traceability, allowing nurses to spend more time with patients and less time preparing therapies.

Canadian retailer Diane's Lingerie named 2023 Independent Retail Ambassador of the Year by Retail Council of Canada

Retrieved on: 
星期三, 四月 19, 2023
Diamond, Amos, Ernst & Young Entrepreneur of the Year Award, Wallachs (clothiers), RCC, Retail Council of Canada, Toronto, Woman, ERA, Entrepreneurship, Nest, Toronto Congress Centre, Cuckoo's Nest (nightclub), Fashion design, Video game

"Diane's Lingerie is a shining example of a retailer that embodies the true spirit of entrepreneurship and community service," said Diane J. Brisebois, President and CEO, Retail Council of Canada.

Key Points: 
  • "Diane's Lingerie is a shining example of a retailer that embodies the true spirit of entrepreneurship and community service," said Diane J. Brisebois, President and CEO, Retail Council of Canada.
  • Diane's Lingerie is a well-deserving recipient of the Independent Retail Ambassador of the Year award, and they represent the best of what the retail industry has to offer."
  • "Diane's Lingerie is honoured to be named Independent Retail Ambassador of the Year.
  • The Independent Retail Ambassador of the Year Award will be presented to Diane's Lingerie at Retail Council of Canada's Excellence in Retailing Awards Gala on May 30, 2023, at the Toronto Congress Centre from 4:30 p.m. to 8:30 p.m.